{"id":525287,"date":"2021-08-09T08:04:41","date_gmt":"2021-08-09T12:04:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/"},"modified":"2021-08-09T08:04:41","modified_gmt":"2021-08-09T12:04:41","slug":"vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/","title":{"rendered":"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Call Scheduled for Thursday, August 12, 2021 at 5:00 pm ET<\/em>\n      <\/p>\n<p align=\"justify\">HIGHLANDS RANCH, Colo., Aug.  09, 2021  (GLOBE NEWSWIRE) &#8212; <strong>\u00a0Vivos Therapeutics, Inc. (\u201cthe Company\u201d) (NASDAQ: VVOS)<\/strong>, a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that it plans to release financial results for the second quarter ended June 30, 2021 after market close on Thursday, August 12, 2021. The Company will conduct a conference call the same day at 5:00 p.m. (Eastern Time) to review the results as well as provide an overview of the Company\u2019s recent milestones and growth strategy.<\/p>\n<p align=\"justify\">To access the conference call, please dial (888) 204-4368, or for international callers, (720) 543-0214. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live call and the replay is 3460553. The replay will be available until August 26, 2021.<\/p>\n<p align=\"justify\">A live webcast of the conference call can be accessed on Vivos\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A0t0R5op5PF01PKkax6jwFu-fSrRnQrRfQIfIQ9rOyujrcO0e9UmZhEQzz6T5MQ8irh-2CcodE3qQzntGgeGbRjV1c4_PQRGTaYMia1JUwExmNFnf6TDTU6MirKP3qxDS39Au5NO5uQ__YjZCpQE0Q==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/vivoslife.com\/investor-relations\/<\/a>. An online archive of the webcast will be available on the Company\u2019s website for 30 days following the call.<\/p>\n<p align=\"justify\">\n        <strong>About Vivos Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos\u2019 oral appliances have proven effective in over 19,000 patients worldwide by more than 1,250 dentists. Combining technologies and protocols that alter the size, shape, and position of the tissues of a patient\u2019s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.<\/p>\n<p align=\"justify\">For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Os3AIlNMvoXuDqotKSzf0y52mLwUop26HntZWMWqTLh-kBBWkjGzCDugCaI37jiVlRRkLOoWWd9ORDo1zxNYPw==\" rel=\"nofollow noopener\" target=\"_blank\">www.vivoslife.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release, the earnings conference call referred to herein, and statements of the Company\u2019s management made in connection therewith contain \u201cforward-looking statements\u201d (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as \u201cmay\u201d, \u201cshould\u201d, \u201cexpects\u201d, \u201cprojects,\u201d \u201cintends\u201d, \u201cplans\u201d, \u201cbelieves\u201d, \u201canticipates\u201d, \u201chopes\u201d, \u201cestimates\u201d and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos\u2019 control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos\u2019 filings with the Securities and Exchange Commission (\u201cSEC\u201d). Vivos\u2019 filings can be obtained free of charge on the SEC\u2019s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos\u2019 expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Edward Loew<br \/>Investor Relations Officer<br \/>(602) 903-0095<br \/>ed@vivoslife.com<\/p>\n<p align=\"justify\">\n        <strong>Media Relations Contact:<\/strong><br \/>\n        <br \/>Caitlin Kasunich \/ Jenny Robles<br \/>KCSA Strategic Communications<br \/>(212) 896-1241 \/ (917) 420-1444<br \/>ckasunich@kcsa.com \/ jrobles@kcsa.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MWJmM2MyMjktZmUxMy00ODMwLWJhYTctMDQyNWVlNzQ1NmU0LTEyMTc0MDY=\/tiny\/Vivos-Therapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Call Scheduled for Thursday, August 12, 2021 at 5:00 pm ET HIGHLANDS RANCH, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Vivos Therapeutics, Inc. (\u201cthe Company\u201d) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that it plans to release financial results for the second quarter ended June 30, 2021 after market close on Thursday, August 12, 2021. The Company will conduct a conference call the same day at 5:00 p.m. (Eastern Time) to review the results as well as provide an overview of the Company\u2019s recent milestones and growth strategy. To access the conference call, please dial (888) 204-4368, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-525287","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Call Scheduled for Thursday, August 12, 2021 at 5:00 pm ET HIGHLANDS RANCH, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Vivos Therapeutics, Inc. (\u201cthe Company\u201d) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that it plans to release financial results for the second quarter ended June 30, 2021 after market close on Thursday, August 12, 2021. The Company will conduct a conference call the same day at 5:00 p.m. (Eastern Time) to review the results as well as provide an overview of the Company\u2019s recent milestones and growth strategy. To access the conference call, please dial (888) 204-4368, &hellip; Continue reading &quot;Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-09T12:04:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call\",\"datePublished\":\"2021-08-09T12:04:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/\"},\"wordCount\":653,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/\",\"name\":\"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM=\",\"datePublished\":\"2021-08-09T12:04:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/","og_locale":"en_US","og_type":"article","og_title":"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call - Market Newsdesk","og_description":"Call Scheduled for Thursday, August 12, 2021 at 5:00 pm ET HIGHLANDS RANCH, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Vivos Therapeutics, Inc. (\u201cthe Company\u201d) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that it plans to release financial results for the second quarter ended June 30, 2021 after market close on Thursday, August 12, 2021. The Company will conduct a conference call the same day at 5:00 p.m. (Eastern Time) to review the results as well as provide an overview of the Company\u2019s recent milestones and growth strategy. To access the conference call, please dial (888) 204-4368, &hellip; Continue reading \"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-09T12:04:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call","datePublished":"2021-08-09T12:04:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/"},"wordCount":653,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/","name":"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM=","datePublished":"2021-08-09T12:04:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTA5MiM0MzQ3NjE3IzIyMDU4NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vivos-therapeutics-schedules-second-quarter-2021-financial-results-conference-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vivos Therapeutics Schedules Second Quarter 2021\u00a0Financial Results Conference Call"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=525287"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525287\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=525287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=525287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=525287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}